Aliases:This biomarker is also known as:
- cell surface glycoprotein MUC18,
- Cell surface glycoprotein P1H12,
- Melanoma cell adhesion molecule,
- Melanoma-associated antigen A32,
- CD146 antigen,
- cell surface glycoprotein P1H12,
- melanoma-associated antigen MUC18,
- Melanoma-associated antigen MUC18,
- melanoma cell adhesion molecule,
- melanoma-associated antigen A32,
- S-endo 1 endothelial-associated antigen,
- melanoma adhesion molecule,
From UniProtKB/Swiss-Prot: Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Head & neck, NOS
No additional data available.
MCAM is one of eight genes on a panel of differentially methylated genes from normal and OSCC clinical samples from patients with heterogenous risk profiles chosen for further validation. The eight genes are: HOXA9, NID2, GATA4, KIF1A, EDNRB, MCAM, DCC, and CALCA.
|QA State:||Under Review|
- Diagnosis of prostate cancer using differentially expressed genes in stroma.
- Expression changes in the stroma of prostate cancer predict subsequent relapse.
- NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.
- An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.